- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03350789
Efficacy and Mechanism of Acupuncture for Chronic Sciatica Using fMRI
Efficacy and Mechanism of Acupuncture on Patients With Chronic Sciatica Using fMRI: A Randomized, Patient-Assessor Blind, Sham-Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 05278
- Recruiting
- Kyung Hee University Hospital at Gangdong
-
Contact:
- Koh-Woon Kim
- Phone Number: 82-2-440-7581
- Email: omdkimkw@khu.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults 19 years of age or more and 70 years of age or less
- clinical diagnosis of chronic sciatica (pain lasting 3 months or more)
- 40mm or more of 100mm VAS for bothersomeness due to sciatica
- volunteers through announcements and advertisements with written informed consent
Exclusion Criteria:
- spinal surgery within the past 6 months
- diagnosis of specific severe diseases resulting in sciatica: malignant tumor, spinal infection, inflammatory sponlylitis
- progressive neurological deficit or severe neurological signs
- other chronic diseases which could disturb the effect of treatments and the results of the study: cardiovascular diseases, autoimmune diseases, renal diseases, diabetic neuropathy, dementia, epilepsy
- inadequate or insafe for the treatment of acupuncture/ electroacupuncture: hemorrhagic diseases, medication of anticoagulant, serious diabetes mellitus vulnerable to infections, serious cardiovascular diseases/ pacemaker, metal materials interior of the body
- currently or might be pregnant
- severe mental illness
- currently participating other clinical trials
- experience of acupuncture or electroacupuncture treatment, or taking medicines which might affect the symptom of pain such as corticosteroids, narcotics, NSAIDs or considered to be inadequate by the investigators within the past week (But they could be included only after going through 2 weeks of wash out period.)
- difficulty of writing informed consent
- inadeguate or insafe for MRI scanning: claustrophobia, metal materials interor of the body
- other inadequate subjects assessed by the study investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Real acupuncture
manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
|
manual acupuncture(0.25mm
diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 & L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today
|
|
Sham Comparator: Sham acupuncture
sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
|
sham acupuncture without skin penetration(0.25mm
diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analogue scale for bothersomeness
Time Frame: baseline, 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1, 4-2, 5, and 8 weeks
|
change in visual analoge scale for bothersomeness [range: 0(better)-100(worse) mm]
|
baseline, 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1, 4-2, 5, and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analogue scale for pain intensity
Time Frame: baseline, 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1, 4-2, 5, and 8 weeks
|
change in visual analogue scale for pain intensity [range: 0(better)-100(worse) mm]
|
baseline, 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1, 4-2, 5, and 8 weeks
|
|
Oswestry Disability Index
Time Frame: week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
change in functional scale: Oswestry Disability Index [10 items, 0-5 points each, total 0(better) -50(worse) points]
|
week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
|
EuroQol 5-Dimension
Time Frame: week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
change in quality of life scale: EuroQol 5-Dimension [5 items, 1-3 points each, total 5(better) -15(worse) points]
|
week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
|
Coping Strategy Questionnaire
Time Frame: week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
change in coping scale: Coping Strategy Questionnaire [8 subscales, total 48 items, 0-6 points each, divided into adaptive coping or disadaptive coping, not better or worse]
|
week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
|
Beck Depression Inventory
Time Frame: week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
change in emotion scale: Beck Depression Inventory [21 items, 1-4 points each, total 21(better) -84(worse) points]
|
week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
|
State-Trait Anxiety Inventory
Time Frame: week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
change in emotion scale: State-Trait Anxiety Inventory [40 items, 1-4 points each, divided into state anxiety or trait anxiety, not better or worse]
|
week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
|
blood oxygenation level dependent in Magnetic Resonance Image, functional
Time Frame: week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
change in blood oxygenation level dependent of steady state and event-related block design scan run in functional magnetic resonance image. cf. functional magnetic resonance image scan run design: REST(6 min)-TASK1(5 min)-3D T1(5 min)-TASK2(5 min)-DTI(6 min)-TASK3(6 min). REST: steady-state resting scan run. TASK1/2: event-related block design, emotion and pain stimulation model scan run. 2 distinct 5-min experiment blocks (each block-20(5*4) stimuli (6 sec, inter-stimulus interval: 9 sec); comprised of visual picture(International Affective Picture System: neutral, negative), pain(low back, hand), picture plus pain). 3D T1: structural image acquisition. DTI: diffusion tensor imaging. TASK3: steady state pain model scan run. Low back extension pain model. |
week 1(before treatment) and week 5(1 week after treatment, primary endpoint)
|
|
Adverse events
Time Frame: baseline, 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1, 4-2, 5, and 8 weeks
|
number of participants with adverse events
|
baseline, 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1, 4-2, 5, and 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mi-Yeon Song, Ph.D., Department of Rehabilitation Medicine of Korean Medicine, Kyung Hee University Hospital at Gangdong
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KHNMC OH 2017-08-004-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Sciatica
-
Kaiser PermanenteCompletedSciatica Pain | Sciatica AcuteUnited States
-
Riphah International UniversityRecruitingSciatica | Sciatica PainPakistan
-
Prince Sattam Bin Abdulaziz UniversityCompleted
-
Istinye UniversityRecruitingSciatica Pain | Sciatica Acute | Mulligan MobilizationTurkey (Türkiye)
-
Primus PharmaceuticalsIllumination HealthRecruitingLumbar Spinal Stenosis | Sciatica AcuteUnited States
-
University of LahoreRecruitingPain | Acute SciaticaPakistan
-
Pakistan Institute of Medical SciencesRiphah International UniversityCompletedSciatica | Sciatica AcutePakistan
-
St George Hospital, AustraliaSt George & Sutherland Medical Research FoundationUnknown
-
University Hospital, MontpellierUnknown
-
Nantes University HospitalTerminatedDiscal SciaticaFrance
Clinical Trials on Real acupuncture
-
West China HospitalNot yet recruitingKnee OsteoarthritisChina
-
Chang Gung Memorial HospitalRecruitingHeadache MigraineTaiwan
-
University of KentuckyNot yet recruitingHot Flashes | Prostate Cancer | Hormone Therapy | AccupunctureUnited States
-
Bo HuangEnrolling by invitation
-
Universidad de la RepublicaActive, not recruitingMyofascial Pain | Craniofacial PainUruguay
-
Kyung Hee University Hospital at GangdongCompleted
-
Federal University of São PauloCompleted
-
Assaf-Harofeh Medical CenterCompletedBack Pain | Anxiety | Neck Pain | Range of MotionIsrael
-
Rambam Health Care CampusCompleted
-
Centre Hospitalier Universitaire de NīmesRecruitingAcupuncture Therapy | Migraine Without AuraFrance